Innoviva Income Taxes 2010-2024 | INVA

Innoviva income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
Innoviva Annual Income Taxes
(Millions of US $)
2023 $14
2022 $67
2021 $76
2020 $60
2019 $42
2018 $-196
2017 $0
2016 $0
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Innoviva Quarterly Income Taxes
(Millions of US $)
2024-09-30 $6
2024-06-30 $-5
2024-03-31 $9
2023-12-31 $-0
2023-09-30 $4
2023-06-30 $5
2023-03-31 $6
2022-12-31 $4
2022-09-30 $57
2022-06-30 $-1
2022-03-31 $7
2021-12-31 $11
2021-09-30 $21
2021-06-30 $25
2021-03-31 $20
2020-12-31 $16
2020-09-30 $9
2020-06-30 $20
2020-03-31 $16
2019-12-31 $12
2019-09-30 $11
2019-06-30 $10
2019-03-31 $9
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30 $-0
2014-06-30 $0
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.195B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03